Introduction
============

Since its discovery in 1960 by J. W. Black, the non-selective beta-blocker propranolol has been widely used in the treatment of hypertension, tachycardia and other cardiac disorders. More recently, propranolol has been introduced as first-line therapy for infantile hemangiomas, the most common soft-tissue tumors of childhood ([@B17]).

As propranolol is a lipophilic molecule, its use in infants raised the question of its ability to passively cross the blood-brain barrier (BBB) and directly activate adrenoreceptors on neuronal cells, and to subsequently impact the neurologic development of the child. Even if many reports have documented that propranolol treatment during infancy does not alter further brain development when compared to child and adolescents from the general population examined several years after cessation of treatment ([@B19], [@B20]; [@B11]; [@B18]), other beta-blockers with hydrophilic properties have been here or there introduced in the treatment of infantile hemangiomas. The most commonly used molecules are nadolol and atenolol, which display hydrophilic properties and are therefore suggested to be unable to cross the BBB ([@B23]; [@B5]) and thus potentially decrease the risk to induce deleterious central effects ([@B6]; [@B25]; [@B33]; [@B2]). However, these assumptions are based on biophysical characteristics of these molecules, and data regarding long-term safety are clearly lacking.

Alternative mechanisms in which some molecules are able to induce signaling pathways in the brain without crossing the blood-brain barrier have been described. One mechanism, that requires diffusible factors between two partners, implies central neurons and endothelial cells located in vascular wall. Indeed, brain endothelial cells have the capacity to produce second messengers such as nitric oxide (NO) to control the release of neurotransmitters ([@B15]). This is especially the case in the mediobasal hypothalamus that includes the median eminence, a circumventricular organ where the BBB is physiologically absent ([@B30], [@B29]; [@B13]). For example, circulating hormones like estrogen ([@B27]) or apelin ([@B8]) induce endothelial NO release, with consequences on physiological functions, such as ovulation and glucose homeostasis, respectively. Hydrogen peroxide (H~2~O~2~) is another way to induce a signaling pathway in this brain region. As previously described for NO signaling, high dose of apelin can modify the release of hypothalamic H~2~O~2~ that could participate to an over-activation of the sympathetic system leading to the development of a type 2 diabetic state ([@B7]). Thus, some molecules can modulate the activity of neuronal cells despite the absence of passage through the BBB and of direct activation of specific receptors on these cells.

The aim of the present study was to investigate whether propranolol, atenolol and nadolol induce the secretion of signaling molecules (i.e., NO and H~2~O~2~) in the hypothalamus, independently of their ability to directly stimulate adrenoreceptors on neuronal cells.

Methods
=======

Animals and Mass Spectrometry Analyses
--------------------------------------

All procedures are performed in accordance with the Directive 2010/63/UE recommendations and with French Veterinary Authorities agreement. *Ex vivo* design and procedures were approved by Ethical Committee (under protocol CEEA-122 2014-53). Eight weeks-old C57BL/6J male mice (*n* = 10/group, mean body weight = 25 g) were orally treated with either propranolol (3 mg/kg/day), atenolol (2 mg/kg/day) or nadolol (1 mg/kg/day) during 7 days, once a day for vehicle, nadolol and atenolol groups (at 8.00 am) and twice a day for propranolol group (at 8.00 am and 6.00 pm). Dose and administration scheme were selected to mimic therapeutic use of these molecules in infants suffering from infantile hemangioma. Mice were euthanized 1 h after the last gavage. Cortex, hypothalamus, cerebellum and brainstem were collected and immediately frozen in liquid nitrogen.

The concentrations of propranolol, atenolol and nadolol were determined after solid phase extraction followed by LC/ESI-MS/MS detection. Tissues were diluted in 9 ml of ultrapure water for 1 g of brain and homogenized by sonication over crushed ice. Atenolol-D7 and propranolol-D7 were used as internal standards. Dynamic concentration range was comprised between 1 and 8000 ng/ml for each compound. The chromatographic peaks for tested compound and internal standards were identified according to their retention times and MRM ion transitions and integrated by analytical software (MassLynx version 4.1, Waters).

Nitric Oxide and Hydrogen Peroxyde *ex vivo* Amperometric Measurements
----------------------------------------------------------------------

Calibration of the electrochemical sensor was performed as previously published ([@B8]; [@B7]; [@B10]; [@B1]). After dissection, hypothalamus was washed in Krebs-Ringer bicarbonate/glucose buffer (pH 7.4) in an atmosphere of 95%O~2~--5%CO~2~ and then immersed in Eppendorf tubes containing the same medium. Spontaneous NO or H~2~O~2~ release was measured at 37°C for 10 min by using either a NO-specific (ISO-NOPF, World Precision Instruments) or a H~2~O~2~-specific (ISO-HPO, World Precision Instruments) amperometric probe implanted in the hypothalamus. Ten micro liter saline solution (vehicle) was injected directly in the survival medium. After 10 min of record, 10 μl beta-blocker solution at increasing concentration was injected (final concentrations: 50 and 250 ng/ml). These concentrations were chosen to mimic plasma concentration of these molecules after an oral therapeutic dose in humans (i.e., approximately 50 ng/ml for propranolol and nadolol, and 250 ng/ml for atenolol). The concentration of NO or H~2~O~2~ gas in solution was measured in real-time (TBR1025, World Precision Instruments). DataTrax2 software (World Precision Instruments) performed data acquisition. Data are expressed as delta variation of NO or H~2~O~2~ release from basal.

Statistical Analyses
--------------------

All statistical analyses were performed using GraphPad Prism 5.0 for Windows (GraphPad Software Inc., San Diego, CA, United States). Two-way ANOVA and Bonferroni's *post hoc* tests when used when appropriate. All values are presented as mean ± SEM. Statistical significance was set at *p* \< 0.05.

Results
=======

Propranolol, Atenolol, and Nadolol Concentration in the Brain
-------------------------------------------------------------

We have first evaluated the capacity of the three beta-blockers to reach brain tissues ([Figure 1](#F1){ref-type="fig"}). As previously described, propranolol is found at a high concentration in the brain after an oral treatment. In the same experimental conditions, the concentrations of nadolol and atenolol are lower in all brain regions, including a neurohemal structure such as the hypothalamus. This last result suggests that hydrophilic molecules cannot massively penetrate into the brain whether or not the BBB is leaky.

![Accumulation of propranolol, atenolol, and nadolol in different brain regions after a chronic oral treatment in mice. Concentration of propranolol, atenolol, and nadolol measured in the cortex, hypothalamus, brainstem, and cerebellum after 1 week of daily oral treatment in mice; *n* = 10/group; ^∗∗∗^*p* \< 0,001 vs. atenolol and nadolol.](fnins-13-00033-g001){#F1}

Hypothalamic NO Release in Response to Beta-Blockers
----------------------------------------------------

At the dose of 50 ng/ml, propranolol rapidly increased NO release from hypothalamus from 5 to 10 min ([Figure 2A](#F2){ref-type="fig"}). Interestingly, atenolol was, at the same dose, also able to increase NO secretion from 6 to 10 min ([Figure 2B](#F2){ref-type="fig"}), while delta variation of NO release in response to nadolol treatment was significantly induced after 9 min ([Figure 2C](#F2){ref-type="fig"}). Taken together, these results show that, at a low dose, all three tested beta-blockers are able to induce NO release from hypothalamus.

![Hypothalamic NO and H~2~O~2~ release in response to propranolol, atenolol, and nadolol treatment. *Ex vivo* NO **(A--F)** and H~2~O~2~ **(G--L)** release from hypothalamus in response to propranolol **(A,D,G,J)**, atenolol **(B,E,H,K)**, or nadolol **(C,F,I,L)** at either low dose 50 ng/mL **(A--C,G--I)** or high dose 250 ng/mL **(D--F,J--L)**; *n* = 10/group; ^∗^*p* \< 0,05, ^∗∗^*p* \< 0,01, and ^∗∗∗^*p* \< 0,001 vs. vehicle.](fnins-13-00033-g002){#F2}

When hypothalamus was treated with propranolol at a higher dose (i.e., 250 ng/ml), no significant variation in NO release was observed ([Figure 2D](#F2){ref-type="fig"}). Surprisingly, atenolol displayed an opposite effect at the high dose compared to low dose treatment by significantly decreasing NO release after 6 min of treatment ([Figure 2E](#F2){ref-type="fig"}). As observed for propranolol, nadolol treatment at this same dose did not induce any significant variation of NO release by the hypothalamus ([Figure 2F](#F2){ref-type="fig"}).

These data indicate that lipophilic propranolol and hydrophilic atenolol and nadolol are all able to induce NO release from the hypothalamus at a low dose. Contrasting results observed at a higher dose suggest that alternative mechanisms may be activated to counterbalance the effects of massive NO release in the brain.

Hypothalamic H~2~O~2~ Release in Response to Beta-Blockers
----------------------------------------------------------

Treatment with a low dose of propranolol (i.e., 50 ng/ml) did not induce any significant variation of H~2~O~2~ release from the hypothalamus ([Figure 2G](#F2){ref-type="fig"}). Similar results have been observed upon atenolol treatment ([Figure 2H](#F2){ref-type="fig"}). However, in response to nadolol at a low dose, delta variation of H~2~O~2~ release from basal significantly increased from 5 min ([Figure 2I](#F2){ref-type="fig"}).

At a higher dose of 250 ng/ml, no significant changes of H~2~O~2~ production were observed in response to propranolol treatment ([Figure 2J](#F2){ref-type="fig"}), while both atenolol ([Figure 2K](#F2){ref-type="fig"}) and nadolol ([Figure 2L](#F2){ref-type="fig"}) treatment rapidly increased H~2~O~2~ release.

Altogether, these results clearly show that, while propranolol treatment does not induce H~2~O~2~ release from the hypothalamic explants at any dose, a high dose of atenolol or nadolol rapidly induce H~2~O~2~ release from the hypothalamus. The amplitude of H~2~O~2~ production is particularly high in response to nadolol treatment, either at a low or high dose.

Discussion
==========

We have shown that, despite the inability of hydrophilic beta-blockers to cross the BBB and thus to accumulate into the brain, all three beta-blockers tested in this study, either lipophilic or hydrophilic, were able to modulate the release of NO and/or H~2~O~2~ in the hypothalamus. As these small molecules can passively diffuse in brain tissue, they could have an impact on neuronal activity of central neurons. This could explain some of the potential deleterious effects of these molecules in the brain such as sleep disorders ([@B6]; [@B25]; [@B16]; [@B17]; [@B28]; [@B14]) and in periphery such as hypoglycemia ([@B12]; [@B26]).

Despite its ability to accumulate into the brain, propranolol failed to increase the release of hypothalamic H~2~O~2~ that is usually associated with oxidative stress ([@B9]; [@B3]). Little is known in the literature to explain the mode of action of propranolol to avoid H~2~O~2~ release. It has been shown that, in the skin of frog, propranolol is able to decrease water permeability induced by arginine vasotocin (AVT) ([@B24]; [@B31]). In this model, aquaporins are translocated at the membrane in response to AVT. We can speculate that propranolol, by acting on aquaporins translocation, could decrease the negative impact of H~2~O~2~, which is known to use aquaporins to cross cell membrane ([@B32]).

The effect of atenolol on hypothalamic NO/H~2~O~2~ release is also unexpected. At low dose, atenolol induces NO release from hypothalamic explants, but at higher dose of 250 ng/ml, corresponding to plasma concentration measured after an oral administration at the therapeutic dose, it decreases NO release and increases H~2~O~2~ secretion. Even if this dual effect seems surprising, our group has previously demonstrated the existence of such physiological phenomenon in another physiological context. Indeed, apelin, an adipokine released by the adipose tissue, stimulates the release of hypothalamic NO at a low dose ([@B8]), but inhibits NO release and stimulates H~2~O~2~ release at a high dose ([@B8]; [@B7]). In our experimental model, this dual effect can be explained by pharmacological and physiological hypotheses. For instance, the decrease of NO release could be due to its interaction with H~2~O~2~ to generate hydroxyl radical ([@B22]).

In addition, we observed that nadolol induces both NO and H~2~O~2~ secretion either at a low or high dose. The low dose reproduces plasma concentration measured after an oral therapeutic dose of nadolol. This result demonstrates that the ability to cross the BBB is not mandatory to induce signaling in the brain, and thus further activation/inactivation of specific neuronal populations.

Finally, the magnitude of NO/H~2~O~2~ release in response to the different treatments also needs to be considered. Indeed, while a release in the range of pM to nM induces physiological effects such as signal transduction and neurotransmission (either beneficial or detrimental depending on targeted neurons), a release in the range of nM to μM induces deleterious effects such as oxidative stress and DNA damage leading to cellular dysfunction ([@B4]; [@B21]). In this study we show that, at a concentration mimicking plasma concentration of the three beta-blockers after a therapeutic dose, propranolol induced a release of 80 nM of NO and no change in H~2~O~2~ production. In contrast, atenolol decreased NO release but increased H2O2 production in the range of μM. Nadolol was responsible of the release of 50 nM of NO and, more importantly, induced a 5 μM release of H~2~O~2~, which is probably leading to oxidative stress and cellular toxicity. Altogether, these data indicate that, even if they do not cross the BBB and do not accumulate in brain tissues, both atenolol and nadolol are able to induce central toxicity.

Of course, our study is limited by the use of murine *ex vivo* models which do not reflect the exact physiological conditions observed *in vivo*. A similar approach (i.e., NO/H~2~O~2~ real-time measurements) could be performed *in vivo* in different brain regions in mice in response to an oral load of beta-blockers ([@B10]).

To conclude, our study brings new elements to decipher the mode of action (and the potential related side effects) of beta-blockers in the brain. The mode of communication through endothelial cells and production of NO/H~2~O~2~ that does not require the entry of a beta-blocker molecule into the brain has to be considered when using such molecule.
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